Treating comorbidities ME/CFS displays an overlap with several autoimmune or immune-mediated diseases that also have chronic fatigue as a main symptom, such as Hashimotos thyroiditis (530), fibromyalgia (FM) (532, 554557), Mast Cell Activation Disorder (532), sleep apnoea (532), IBS (532), secondary depression or anxiety (532), Ehlers-Danlos syndrome (532), and PoTS (532, 558563)
Peptides may offer slower but more sustainable results by improving metabolic health and hormonal balance, while Ozempic provides faster weight loss through appetite suppression
Time-sensitive US update: FDA briefing documents published in May 2026 proposed that BPC-157 and TB-500-related substances should not be added to the US 503A Bulks List
Research shows that understanding the differences between these compounds will help scientists design better studies and improve content in metabolic research